BioLineRx (BLRX) Long-Term Debt Repayments (2013 - 2021)
BioLineRx (BLRX) posted quarterly Long-Term Debt Repayments of -$1.1 million for Q4 2025, up 90.49% year-over-year from -$597943.8 in Q4 2024, and down 1.79% quarter-over-quarter from -$1.1 million in Q3 2025.
Powered by 
Analysis
BioLineRx (BLRX) Long-Term Debt Repayments (2013 - 2021) Analysis & Trends
BioLineRx's Long-Term Debt Repayments history runs 12 years deep, the most recent figure standing at -$1.1 million for Q4 2025.
- In Q4 2025, Long-Term Debt Repayments rose 90.49% year-over-year to -$1.1 million; the TTM figure through Dec 2025 stood at -$4.5 million (up 68.84% YoY), while the FY2025 annual figure was -$4.5 million, up 68.84% from the prior year.
- Long-Term Debt Repayments for Q4 2025 stood at -$1.1 million, down from -$1.1 million in the prior quarter.
- The five-year high for Long-Term Debt Repayments was -$741000.0 in Q4 2023, with the low at -$12.0 million in Q4 2024.
- The 5-year median for Long-Term Debt Repayments is -$895000.0 (2022), against an average of -$1.6 million.
- The sharpest annual moves came in 2024 and 2025: Long-Term Debt Repayments plunged 1515.65% in 2024, then jumped 90.49% in 2025.
- BioLineRx's Long-Term Debt Repayments stood at -$874000.0 in 2021, then dropped by 16.7% to -$1.0 million in 2022, then advanced by 27.35% to -$741000.0 in 2023, then slumped by 1515.65% to -$12.0 million in 2024, then surged by 90.49% to -$1.1 million in 2025.
- Business Quant data shows BLRX's Long-Term Debt Repayments at -$1.1 million in Q4 2025, -$1.1 million in Q3 2025, and -$1.1 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 17.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | - |
| 10 | BioLineRx | 6.46 Bn | 6.46 Bn | 235,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | -874,000.00 |
| Sep 30, 2021 | -854,000.00 |
| Jun 30, 2021 | -834,000.00 |
| Mar 31, 2021 | -814,000.00 |
| Dec 31, 2020 | -795,000.00 |
| Sep 30, 2020 | -1.01 Mn |
| Jun 30, 2020 | -649,000.00 |
| Mar 31, 2020 | -682,000.00 |
| Dec 31, 2019 | -819,000.00 |
| Sep 30, 2019 | -23,000.00 |
| Jun 30, 2019 | -24,000.00 |
| Mar 31, 2019 | -23,000.00 |
| Dec 31, 2018 | -248,000.00 |
| Sep 30, 2018 | -23,000.00 |
| Jun 30, 2018 | -24,000.00 |
| Mar 31, 2018 | -23,000.00 |
| Dec 31, 2017 | -23,000.00 |
| Sep 30, 2017 | -23,000.00 |
| Jun 30, 2017 | -24,000.00 |
| Mar 31, 2017 | -23,000.00 |